1. Home
  2. AGMB vs CBLL Comparison

AGMB vs CBLL Comparison

Compare AGMB & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AGMB

AgomAb Therapeutics NV American Depositary Shares

N/A

Current Price

$12.86

Market Cap

677.9M

Sector

Health Care

ML Signal

N/A

Logo CeriBell Inc.

CBLL

CeriBell Inc.

HOLD

Current Price

$18.77

Market Cap

750.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGMB
CBLL
Founded
2017
2014
Country
Belgium
United States
Employees
N/A
280
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
677.9M
750.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AGMB
CBLL
Price
$12.86
$18.77
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$32.00
$24.67
AVG Volume (30 Days)
115.4K
281.3K
Earning Date
06-16-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$29.57
Revenue Next Year
N/A
$28.44
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.50
$10.01
52 Week High
$17.45
$24.33

Technical Indicators

Market Signals
Indicator
AGMB
CBLL
Relative Strength Index (RSI) 42.89 47.50
Support Level N/A $18.78
Resistance Level $15.05 $19.88
Average True Range (ATR) 1.33 0.76
MACD -0.16 0.13
Stochastic Oscillator 51.92 52.86

Price Performance

Historical Comparison
AGMB
CBLL

About AGMB AgomAb Therapeutics NV American Depositary Shares

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.

About CBLL CeriBell Inc.

CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.

Share on Social Networks: